To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]...To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.展开更多
基金supported by grants from the project(No.RDJP2022-71)Peking University People’s Hospital Scientific Research Development Funds and the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2019-I2M-5-034).
文摘To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.
